We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HEIQ Heiq Plc

0.10 (1.16%)
15 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Heiq Plc LSE:HEIQ London Ordinary Share GB00BN2CJ299 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 1.16% 8.70 8.62 8.78 8.82 8.50 8.52 2,919,690 16:01:14
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 48.1M -29.25M -0.2081 -0.42 12.23M
Heiq Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEIQ. The last closing price for Heiq was 8.60p. Over the last year, Heiq shares have traded in a share price range of 8.00p to 26.50p.

Heiq currently has 140,537,900 shares in issue. The market capitalisation of Heiq is £12.23 million. Heiq has a price to earnings ratio (PE ratio) of -0.42.

Heiq Share Discussion Threads

Showing 201 to 224 of 875 messages
Chat Pages: Latest  11  10  9  8  7  6  5  4  3  2  1
Broken key levels with the sellers in size at 204-205p from recent days now appearing to have been cleared on the back of today's bullish news. However, as per the previous post, there sure did appear to be some suspect buying in the afternoon yesterday.

<--- Been doing this a while, notice things :-)

Some SCSW for sure (though the bulk of that is always the Monday following the release and then some into Tuesday morning where it can fade off), some folk following other buying but surely not all can be explained by the errr...material pick up of buying in the afternoon.

It happens, just saying.

Not fully up to speed with this one on the fundamentals. It looks a speculative one that appears to be expensive but with so many avenues and a big market to tackle, it could double and still look cheap.

Piggybacking off the recent buying here, but could be one of those just to tuck away and leave for a few years but who can do stuff like that anyway? That's a skill in itself!

All imo

This mornings deal with Chrisal is a good earnings enhancing deal that fits like a glove with HeiQ and its growth and they are targeting cross selling and synergies with the bottling plant definitely an attraction. The structure of the deal with 51% and the controlling interest purchased is also good for the everyday running of the company is being left to the present Management but The CEO and other Member of the HeiQ Board will join The Chrisal Board to participate and steer things at Board level and without distraction from any other projects. All paid for as well.
this guy has a good track record and talks about Heiq from about 30:25
I am surprised the announcement has had little effect on share price
Should get good press tomoz

And upgrade

3 March 2021

HeiQ Plc

Acquisition of 51% of Industrial Biotech Business, Chrisal

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has signed an agreement to acquire 51% of the share capital and voting rights of Chrisal N.V., Belgium ("Chrisal", "the Acquisition"). The Acquisition is for a consideration of €7.5 million, with €5.0 million payable in cash and €2.5 million through the issue of 1,101,928 new ordinary shares by HeiQ. On completion, Chrisal will be renamed HeiQ Chrisal.

Chrisal is a profitable industrial biotechnology company and a leader in innovative ingredients and consumer products that incorporate the benefits of probiotics and synbiotics. It has 120 products within its three technology platforms that create healthy and sustainable microbial ecosystems. The application of its proprietary technology includes cosmetics, personal care, textiles, wound dressings, water purification, air treatment and cleaning products. Chrisal has recently developed a synbiotic interior cleaner, Synbio®, for healthcare and hospitals, a project sponsored by The Gates Foundation. Early results have indicated Synbio® cleaners to be equal to disinfectants and detergents but without bacterial resistance downsides, while offering enhanced cleaning performance.

The Acquisition is aligned with HeiQ's strategy of becoming a global leader in materials innovation. It also solidifies HeiQ's position as a profitable and fast-growing pioneer in the $24 billion global textile chemicals market. HeiQ already directly serves the $10 billion antimicrobial textile market with its HeiQ Viroblock and HeiQ Pure technology platforms and the Acquisition will strengthen its presence with a complementary probiotic platform while enabling it to enter the new adjacent and lucrative markets of surface hygiene treatment, water purification and probiotic personal care.

Additional Highlights
· Chrisal recorded revenue of €5.5 million for the 12 months to 31 December 2020, an increase of 62% compared to 2019, and an operating profit of €1.6 million (28.9%) - unaudited.

· Chrisal has over 500 commercial customers in 25 countries, including hospitals, food and cosmetic manufacturers, presenting HeiQ with compelling cross-selling opportunities for its existing core product range. Chrisal will benefit from HeiQ's extensive customer and distribution network, as well as its marketing prowess.

· Chrisal customers include Q viva, Ahava, Atena-Alfa, Probilife, Sonax, Woellner and Greenspeed

· The Acquisition includes a bottling facility in Belgium. This is an important infrastructure requirement for HeiQ's ambitions in functional textile aftercare and other fields.

· The current Chrisal President and Founder Corrie Gielen and its CEO/CTO Dr. Robin Temmerman will continue to lead the business, supported by the existing Chrisal team.

· HeiQ co-Founder and Group CEO Carlo Centonze as well as Group CFO Xaver Hangartner will join the HeiQ Chrisal Board of Directors and will explore further synergies over the course of 2021.

· HeiQ Chrisal will be responsible for the creation, production and commercialisation of its products, with HeiQ acting as its corporate service hub and extended commercialization arm.

· Chrisal's patented technology carries the prestigious EU Ecolabel, a label of excellence that is awarded solely to products meeting high environmental standards throughout their lifecycle.

HeiQ co-founder and CEO Carlo Centonze said:

"The acquisition of a majority stake in Chrisal brings multiple benefits to HeiQ and its shareholders. HeiQ Chrisal will provide us with revenue from other fast-growth markets adjacent to those we serve already, as well as exciting cross-selling opportunities for our and their existing core product range. The acquisition will progress our direct to consumer offer and enlarges our product offering to hygiene-sensitive environments, such as the healthcare sector.

"Chrisal's technology platform includes an anti-allergen effect for mattresses and bedding, microbial and viral protection for surfaces, anti-inflammatory effects in wound dressings, probiotic skin enhancing cosmetics, algae and biofilm control in drinking water as well as advanced synbiotic protection to replace the resistance-creating antibiotics in animal husbandry. We are particularly excited about Chrisal's synbiotic technology solution for healthcare and hospitals for which full clinical results are due to be published imminently in a leading journal.

"HeiQ is increasingly becoming more than a textile technology company; we are innovating materials more broadly. This acquisition of a leading probiotics business is aimed at making HeiQ a leader in probiotic innovation, positioning us well to serve many lucrative segments of this fast growth USD 50 billion market.

"Chrisal's culture of entrepreneurship, people empowerment, sustainability, innovation and lean processes are a perfect match with HeiQ. I expect this partnership to become a great success and we will look forward to working closely with Corrie, Robin and the rest of the Chrisal team."

Corrie Gielen, President of Chrisal commented:
"For 30 years Chrisal has built on new technologies to improve our world in a sustainable way. With our latest patented Synbio® technology we have found the best solution to strengthen products, people and our environment. We are confident that the new partnership with HeiQ will bring us the additional competences and network needed to globalize this beautiful and groundbreaking technology. Together we combine the best of nature with the latest in science to make the difference for a better world."

Further Information on Chrisal:

Chrisal is an industrial biotechnology leader in prebiotic, probiotic and synbiotic technologies and products. With its 120 products, Chrisal serves commercial and consumer customers operating in the markets of cosmetics, personal care, textiles, wound dressings, water and air purification and cleaning solutions for hospitals and animal husbandry. Early results from clinical trials for Chrisal's patented Synbio®, an active synbiotic surface cleaner, suggest that it could be the next generation technology to probiotic surface cleaners, such as Reckitt Benckiser's VEO. Chrisal technology carries the prestigious EU Ecolabel, a label of environmental excellence that is awarded solely to products meeting high environmental standards throughout their lifecycle.

The industrial biotech acquisition will provide HeiQ access to the technology platform of prebiotics, probiotics and postbiotics for bio-based odor & stain control for carpet & footwear, anti-allergen effect in mattress and bedding, microbial and viral protection for surfaces, anti-inflammatory effect in wound dressings, probiotic skin enhancing cosmetics, algae and biofilm control in drinking water as well as advanced synbiotic protection replacing the resistance-creating antibiotics in animal husbandry. With this strategic acquisition HeiQ enters the broader market of surface management and accesses a bio-based green complementary technology platform to its antimicrobials.

Chrisal's 120 products strengthen HeiQ's global product offering and will facilitate HeiQ's existing technology platforms into new markets.

Chrisal has a large, efficient manufacturing footprint in Lommel, Belgium and brings into the HeiQ group the strategic capability of bottling, a step required for HeiQ's B2C products ambitions in functional textile aftercare and other fields. Chrisal also includes a microbiology and molecular diagnostics lab for R&D and QC activities.

HeiQ Chrisal, the new corporate name for Chrisal, will continue to be led by President and Founder Corrie Gielen, its CEO/CTO Dr. Robin Temmerman as well as the entire Chrisal team. The entrepreneurial drive will be strengthened by HeiQ's Group support functions in Rapid & Deep R&D, Branding & Marketing, Regulatory and Compliance as well as Commercialisation. HeiQ co-Founder and Group CEO Carlo Centonze as well as Group CFO Xaver Hangartner will join the HeiQ Chrisal Board of Directors.

HeiQ Chrisal will be responsible for the creation, production and commercialization of its products, with the HeiQ Group acting as its corporate service hub and extended commercialization arm. Together, the newly enlarged Board will explore further synergies over the course of 2021.

Issue of Equity and Total Voting Rights

The Company will issue 1,101,928 new ordinary shares ("Consideration Shares") to the sellers of Chrisal, at a price of 1.9596p per share, which is the average 5 day closing price prior to signing, in order to part satisfy the consideration due. Applications will be made for the Consideration Shares to be admitted to the standard segment of the Official List, and to trading on the London Stock Exchange's Main Market ("Admission").

It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 8.00 a.m. on 9 March 2021.

Following Admission, the total number of Ordinary Shares in issue will be 126'993'832 and the total number of voting rights will therefore be 126'993'832. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information.

For further information, please contact:

HeiQ Plc

Sphere252 Mar '21 - 16:05 - 214 of 215
0 1 0
Is the bulk of today's buying on the back of that? Is that new?

old news see 188

news tomorrow? Buying into the close
Is the bulk of today's buying on the back of that? Is that new?

That looks like Heiq kit

If they announce a contract in an RNS it would send this through the 52-wk high of 250p

nobilis there seems to be a buyer now showing their hand. Hopefully we shouldn't have too long to wait to get back to 240p and far beyond that. I hope I haven't spoke too soon.
The Nanotechnology thing will send into orbit one day
Great stock but the market makers seem to blow hot and cold with lots of trades followed by days of very little when they try to get greedy. There really is no need for a 5 point spread.
It's with IG, I'll ask them
Strange as I own it in my SIPP with HL
Can't buy this in my SIPP ("invalid tax wrapper"), but can in ISA...
Taken a few this morning though hard to buy so haven't managed many.

The differences between the listings can be explored here:

As HEIQ is on the standard list (and not the premium list), it is not eligible to be part of the FTSE series of UK indices.

Hope this helps.

All imo

Sharescope doesn't show HEIQ as being a part of any index so maybe it isn't.
The LSE announcement on 7th December states

"The Company’s shares were admitted to the Standard Segment of the Official List of the Financial Conduct Authority at 8:00 am on Monday 7th December 2020 by way of a reverse take over into Auctus Growth Plc. The admission follows an oversubscribed placing and subscription, raising £60 million (before expenses) from institutional and other investors."

i knew that but which segment is it small cap, fledgeling or 250 footsie?
It’s a main listing.
dr biotech
no unfortunately i googled it and there no clarification- does that measn its not on aim- does this make any difference to investing?
SSX3 whatever that is, does that answer your question?
melton john
can someone tell me please on what segment of the primary market thi share is on
Chat Pages: Latest  11  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock